---
title: "How to Research Nasdaq Biotechnology Index Companies"
description: "A useful biotechnology research process begins with company stage and asset concentration."
canonical: https://www.getswoopr.com/stocks/indexes/nasdaq-biotechnology/biotech-research-guide/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# How to Research Nasdaq Biotechnology Index Companies

## Direct answer

Researching **Nasdaq Biotechnology Index (NBI)** companies requires a framework built around clinical-stage risk: pipeline stage and read-out timeline, cash runway relative to the next catalyst, and regulatory pathway. Unlike mature-company analysis, NBI constituents span pre-revenue clinical-stage firms through large-cap integrated biopharma, so the right analytical lens depends on where a company sits in its development cycle. This guide covers the key data sources, valuation approaches, and risk factors specific to biotech equity research.

## # How to Research Nasdaq Biotechnology Index Companies

A useful biotechnology research process begins with company stage and asset concentration.

## Clinical-stage companies

Start with:

- lead asset;
- target/biology;
- indication;
- trial design;
- endpoint;
- human efficacy;
- safety;
- next catalyst;
- cash runway;
- dilution.

## Commercial-stage companies

Start with:

- product-level revenue;
- demand/volume;
- net pricing;
- payer access;
- patent/exclusivity;
- lifecycle management;
- free cash flow;
- pipeline replacement.

## Platform companies

Ask whether the platform has been validated repeatedly in humans or through diversified partner economics.

## Gene/cell therapy

Add:

- delivery;
- durability;
- CMC/manufacturing;
- long-term follow-up;
- treatment-center capacity.

## Diagnostics/tools

Add:

- installed base;
- test/sample volumes;
- recurring consumables;
- reimbursement/research funding;
- workflow retention.

The Swoopr company pages in this package use 19 research archetypes instead of one generic biotechnology template.

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).
